Pharm'Up 
In a major regulatory shift, the Drugs Technical Advisory Board (DTAB) has reaffirmed its decision to bring all antimicrobial drugs under the strict definition of “New Drugs” as per the New Drugs and Clinical Trials Rules, 2019.
The move, finalized during the board’s 93rd meeting in New Delhi, aims to provide the government with greater oversight over the efficacy, safety, and rational use of antibiotics, antivirals, and antifungals.
Stricter Oversight for Future Molecules
By classifying antimicrobials as “New Drugs,” the CDSCO will now require more rigorous clinical data and regulatory approvals before any new version of these life-saving medicines can hit the market. This classification typically mandates:
- Enhanced Clinical Data: Proof of efficacy specifically tailored to the Indian population.
- Post-Marketing Surveillance: Mandatory monitoring of side effects and resistance patterns for a fixed period after launch.
- Controlled Licensing: A centralized approval process that prevents the unchecked proliferation of irrational drug combinations.
A “Prospective” Approach for Industry Stability
Acknowledging the potential for supply chain disruption, the DTAB has recommended that this change be implemented prospectively.
This is a significant relief for pharmaceutical manufacturers, as it means currently licensed products and existing brands will not be hit with new compliance requirements. The “New Drug” status will only apply to future applications and new antimicrobial molecules entering the Indian market.
Strengthening the Fight Against AMR
India remains a global hotspot for Antimicrobial Resistance (AMR). This regulatory reform is a cornerstone of a broader strategy to ensure that antibiotics remain effective. By treating these drugs as specialized “New Drugs” rather than standard commodities, regulators can better manage how they are introduced and used across the country.
A detailed framework for the new licensing pathway is expected to be circulated among stakeholders soon, providing a clear roadmap for the transition.
About the Author
